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Abstract
Background: Blastocystis sp. is currently the most common intestinal protist found in human feces and considered
an emerging parasite with a worldwide distribution. Because of its potential impact in public health, we reinforced
the picture of Blastocystis sp. prevalence and molecular subtype distribution in Africa by performing the first survey
of this parasite in Senegal.
Methods: Stool samples from 93 symptomatic presenting with various gastrointestinal disorders or asymptomatic
children living in three villages of the Senegal River Basin were tested for the presence of Blastocystis sp. by non-
quantitative and quantitative PCR using primer pairs targeting the SSU rDNA gene. Positive samples were subtyped
to investigate the frequency of Blastocystis sp. subtypes in our cohort and the distribution of subtypes in the
symptomatic and asymptomatic groups of children.
Results: By the use of molecular tools, all 93 samples were found to be positive for Blastocystis sp. indicating a
striking parasite prevalence of 100%. Mixed infections by two or three subtypes were identified in eight individuals.
Among a total of 103 subtyped isolates, subtype 3 was most abundant (49.5%) followed by subtype 1 (28.2%),
subtype 2 (20.4%) and subtype 4 (1.9%). Subtype 3 was dominant in the symptomatic group while subtypes 1 and
2 were detected with equal frequency in both symptomatic and asymptomatic groups. The distribution of subtypes
was compared with those available in other African countries and worldwide. Comparison confirmed that subtype
4 is much less frequently detected or absent in Africa while it is commonly found in Europe. Potential sources of
Blastocystis sp. infection including human-to-human, zoonotic, and waterborne transmissions were also discussed.
Conclusions: The prevalence of Blastocystis sp. in our Senegalese population was the highest prevalence ever
recovered worldwide for this parasite by reaching 100%. All cases were caused by subtypes 1, 2, 3 and 4 with a
predominance of subtype 3. More than half of the children infected by Blastocystis sp. presented various
gastrointestinal disorders. Such high prevalence of blastocystosis in developing countries makes its control a real
challenge for public health authorities.
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Background
Blastocystis sp. is an anaerobic protist that inhabits the
gastrointestinal tract of humans and many groups of ani-
mals [1-4]. This cosmopolitan enteric parasite with a
worldwide distribution [5] is often identified as the most
common unicellular eukaryote reported in human fecal
samples [1]. Indeed, its prevalence may exceed 50% in
developing countries [6,7] and reach 20% in industrial-
ized countries [8,9]. These differences may be explained
by poor sanitary conditions, close animal contact, and
consumption of contaminated food or water [10-12].
Such prevalence also suggests large-scale human-to-
human [13], waterborne, and zoonotic transmissions for
Blastocystis sp. [14]. Numerous studies have demon-
strated the resistance of cysts of the parasite in feces and
environmental sources [15] highlighting the fecal-oral
route as the main mode of transmission of Blastocystis
sp. Moreover, a higher risk of infection has been identi-
fied in food and animal handlers, providing conclusive
evidence on the transmission of the parasite between
humans and animals [16,17].
At the morphological level, Blastocystis sp. isolates
from humans and animals have been reported to be
roughly indistinguishable [1]. However, extensive genetic
diversity among Blastocystis sp. isolates has been re-
ported based on the comparison of the small-subunit
(SSU) rDNA gene sequence [18] leading to the classifi-
cation of Blastocystis sp. isolates into subtypes (STs)
[19]. To date, according to recent epidemiological sur-
veys in human and animal populations, 17 STs have
been identified [2] but it is highly likely that other STs
remain yet to be uncovered. Among the 17 STs, nine of
them have been detected in humans with a varying
prevalence [5]. Indeed, only four of them are frequent
(ST1, ST2, ST3 and ST4) and represent around 90% of
the subtyped isolates. A majority of human infections
with Blastocystis sp. is attributable to ST3 but the distri-
bution of the four predominant STs may vary among the
areas studied. Thereby, ST4 is almost as common as
ST1 and ST3 in some European countries but seems
rare or completely absent in Africa, Asia, and America
[5,20]. The other STs that are common in animal hosts
i.e. ST5 to ST9, are rarely found in humans and are most
likely the result of zoonotic transmission.
As Blastocystis sp. can be found in both symptomatic
and asymptomatic patients its clinical relevance remained
uncertain [1]. However, a converging bundle of recent
in vivo, in vitro and genomic data strongly suggests that
this microorganism may be pathogen [21-24] and allows
proposing a model for pathogenesis of this parasite [25]
particularly involving virulence factors as cysteine pro-
teases [26,27]. Therefore, Blastocystis sp. should be associ-
ated with a variety of non-specific gastrointestinal
disorders including diarrhea, abdominal pain, nausea and
vomiting [1,22] and also suspected to be linked to irritable
bowel syndrome (IBS) [25,28] and chronic or acute urti-
carial lesions [29,30]. In addition, Blastocystis sp. has
increasingly been implicated in diarrheal illness in im-
munocompromised individuals including HIV/AIDS and
cancer patients and transplant recipients [31,32].
It has long been suggested that the pathogenesis of
Blastocystis sp. may be dependent upon ST but recent
epidemiological data remain contradictory [8,29,33-36].
Nevertheless, the likely pathogenic power of Blastocystis
sp. coupled to its high prevalence in the human popula-
tion raise crucial questions about its current burden in
public health. Consequently, information on the preva-
lence of the parasite and the distribution of STs are
starting to emerge in still poorly studied geographic
areas as Africa. To date the available data concern only
few African countries of the North and West such as
Egypt [21,37,38], Libya, Nigeria, and Liberia [5] and one
Eastern African country, Tanzania [39]. Therefore, the
aim of the present study was to reinforce the picture of
Blastocystis sp. prevalence and ST distribution in Africa
by performing the first survey of this parasite in Senegal.
In this epidemiological study, we described the preva-
lence of Blastocystis sp. infection and ST distribution in
a cohort of Senegalese children living in 3 rural villages
in close contact with animals and with poor or no access
to clean water and sanitation. The distribution of Blasto-
cystis sp. STs in both asymptomatic and symptomatic in-
dividuals was investigated together with potential risk
factors for transmission of the parasite.
Methods
Cohort and collection of samples
This work has been carried out as part of the “SchistoVAN”
project (clinicaltrials.gov ID NCT01553552), sponsored
by the Biomedical Research Centre EPLS (Saint-Louis,
Senegal) (www.espoir-sante.org). The present study was
approved by the National Ethics Committee of the
Ministry of Health of Senegal (September 2011; protocol
number SEN11/43, clinicaltrials.gov: NCT01553552). Oral
and written informed consents were obtained from the
parents or the legal guardians of the children in accord-
ance with the Code of Ethics of the World Medical associ-
ation (Declaration of Helsinki). Children enrolled in the
present study formed a sub-cohort of the “AnoPalAno-
Vac” project (clinicaltrials.gov ID NCT01545115) and
were recruited on the basis of their age (6 to 10 years of
age in October 2011) through village nurses, healthcare
workers in the community and school directors. Date of
birth was ascertained from vaccination cards or school
register. A standardized questionnaire was completed for
each child (see Additional file 1). In particular, children
were asked about each gastrointestinal symptom individu-
ally including abdominal pain, diarrhea, and vomiting.
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This cross-sectional study was conducted in October
2011, in 3 villages of the Podor district located in northern
Senegal: Agniam Towguel (16°32′N-14°48′W; total popu-
lation (TP): 989; several temporary ponds, traditional
housing, irrigated crops), Fanaye Diery (16°32′N-15°13′W;
TP: 6781; animal husbandry, irrigated crops, some urban-
ized habitat), and Niandane (16°35′N-14°59′W; TP: 5100;
rice and banana farming, irrigated crops, some urbanized
habitat, no access to running water). In this region, the cli-
mate is Sahelian, with annual rainfall between July and
September. Mean temperature ranges between 20°C and
30°C during the cool season (November to February) and
between 25°C and 38°C during the warm season (March
to October). In this study, stool samples were collected
from 93 symptomatic and asymptomatic children
(Agniam = 17; Fanaye = 38; Niandane = 38) presenting or
not gastrointestinal disorders. These boys (n = 46) and
girls (n = 47) were aged 6 to 10 years (median age 8.4;
quartiles: 6.6; 9.5) (Table 1). Children presented no symp-
toms of severe illness and/or fever and were subject to a
questionnaire that was designed to collect clinical data
especially regarding recent diarrhea, vomiting, and ab-
dominal pain. For storage and transport at −20°C to Lille,
stool samples were added in Stool Transport and Recov-
ery (S.T.A.R.) buffer (Roche) in a ratio of 1:3 according to
the manufacturer’s recommendations then homogenized
by shaking.
DNA extraction and molecular subtyping of Blastocystis
sp. isolates
Samples stored in S.T.A.R. buffer were stirred and then
centrifuged for 1 min at 1,000 g. Total genomic DNA
was extracted from 200 μl of the cleared stool super-
natant using the QiaAMP DNA Stool Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s in-
structions. For each sample, 5 μl of extracted DNA was
submitted to non-quantitative Polymerase Chain Reac-
tions (non-qPCRs) as previously described using two in-
dependent pairs of Blastocystis sp.-specific primers
designed by Scicluna et al. [40] and Poirier et al. [20],
both targeting the small subunit (SSU) rDNA coding re-
gion. The respective 600 bp- and 320 bp-amplified do-
mains have been shown to contain sufficient information
for accurate subtyping of Blastocystis sp. isolates [20,40].
Non-qPCR amplifications were carried out in 50 μl ac-
cording to standard conditions for Platinum Taq High-
Fidelity DNA polymerase (Invitrogen). For each DNA
sample, the non-qPCR product with the highest intensity
on agarose gel was purified and sequenced. Direct se-
quencing of few non-qPCR products generated mixed
signals that could reflect infections by different STs or
was of poor quality probably due to a too small amount
of parasite DNA matrix. Because of the difficulty in inter-
preting the corresponding DNA sequencing chromatograms,
same samples were re-analyzed by non-qPCRs and posi-
tive bands of the expected sizes were purified and cloned
as previously described [41]. Three positive clones con-
taining inserts were arbitrarily selected for each sample
and sequenced on both strands. The DNA samples nega-
tive by non-qPCRs were subsequently amplified using the
real time qPCR assay developed by Poirier et al. [20]. Due
to the high sensitivity of this detection method, various
controls were performed to prevent artifacts related to
contamination through different sources: DNA extraction
controls (isolation of DNAs without stool and from a
Blastocystis sp.-negative stool) subsequently used in qPCR
assays and negative (DNA matrix replaced by water) and
positive (DNA obtained from a Blastocystis sp. ST4 cul-
ture) qPCR controls. The expected 320 bp-amplified vari-
able region of the SSU rRNA gene was directly sequenced
for subtyping. The SSU rRNA gene sequences obtained in
this study have been deposited in GenBank under ac-
cession numbers KF848509 to KF848624. Obtained se-
quences were compared with all Blastocystis sp. SSU
rRNA gene sequences available from the National Centre
for Biotechnology Information (NCBI) using the BLAST
program. STs were identified by determining the exact
match or closest similarity against all known Blastocystis
sp. STs according to the updated classification by Alfellani
et al. [2].
Results and discussion
Screening for Blastocystis sp. in a cohort of Senegalese
children using molecular methods
In this study, fecal samples were collected from 93 chil-
dren, 46 boys and 47 girls, aged 6 to 10 years and living
in 3 villages situated in the north of Senegal. This cohort
consisted of two groups: one symptomatic composed of
54 children presenting variously with abdominal pain,
vomiting, and diarrhea and one asymptomatic includ-
ing 39 other children (Table 1). All 93 samples were
screened for Blastocystis sp. by non-qPCR and qPCR
methods using specific primer pairs amplifying distinct
domains of the SSU rDNA coding region [20,40]. Non-
qPCR products were directly sequenced or subsequently
cloned whether the resulting sequence chromatogram
showed double or poor quality signals. In the latter case
that involved 32 samples, three positive clones contain-
ing inserts were arbitrarily selected and sequenced.
Overall, 71 samples were identified as positive for Blas-
tocystis sp. by non-qPCR methods. The remaining 22
samples negative by non-qPCR nevertheless proved to
be positive for the parasite by qPCR. Thereby, by means
of these different molecular approaches, Blastocystis sp.
was recognized in 100% of stool samples of this
Senegalese population. To our knowledge this represents
the highest prevalence ever recovered worldwide for this
parasite.
El Safadi et al. BMC Infectious Diseases 2014, 14:164 Page 3 of 11
http://www.biomedcentral.com/1471-2334/14/164
Table 1 Clinical data and Blastocystis sp. STs among symptomatic and asymptomatic patients in Senegal







DSS1 M/6.2 Abdominal pain 1 KF848509
DSS2 F/5.9 Abdominal pain, diarrhea 3 (Sc) 0 KF848510
DSS3 M/6.8 3 (Sc) KF848511
DSS4 F/6.1 Abdominal pain, vomiting 1 (Sc) KF848512
DSS5 M/8.3 3 KF848513
DSS6 M/7.3 Abdominal pain, diarrhea 1 (Sc) KF848514
DSS7 F/5.9 3 KF848515
DSS8 M/6.8 Abdominal pain, vomiting 1 (Sc) KF848516
DSS9 F/9.2 Abdominal pain 3 KF848517
DSS10 M/9.7 Vomiting 3 (Sc) 0 KF848518
DSS11 F/10 Diarrhea, vomiting 3 (Sc) KF848519
DSS12 M/8.8 Abdominal pain, vomiting 3 KF848520
DSS13 F/8.6 Abdominal pain 1 (Sc) KF848521
DSS14 M/7 2 (Sc) 0 KF848522
DSS15 F/7.7 2 (Sc) KF848523
DSS16 M/6.9 3 KF848524
DSS17 F/7.7 3 KF848525
DSS18 F/6.1 3 (Sc) 0 to14 KF848526-7
DSS19 M/8.7 2 KF848528
DSS20 M/9.7 Abdominal pain 2 (Sc) KF848529
DSS21 F/6 Abdominal pain 1 (Sc) KF848530
DSS22 M/10.1 Abdominal pain 3 (Sc) KF848531
DSS23 M/7.7 Mixed 2 and 3 (P) 0 KF848532-3
DSS24 F/6.4 1 (Sc) KF848534
DSS25 F/9.6 Abdominal pain Mixed 3 and 4 (Sc) 0 to 4 KF848535-7
DSS26 F/6.5 Abdominal pain Mixed 1, 2 and 3(Sc) KF848538-40
DSS27 M/7.2 3 (Sc) KF848541
DSS28 M/8 3 (Sc) KF848542
DSS29 F/7.3 2 KF848543
DSS30 M/5.8 Abdominal pain 1 KF848544
DSS31 F/8.6 Abdominal pain 2 (Sc) KF848545
DSS32 M/6.6 3 (Sc) KF848546
DSS33 M/7.7 Abdominal pain Mixed 2 and 3 (Sc) 0 KF848547-8
DSS34 M/9.5 Vomiting 3 (Sc) KF848549
DSS35 M/7.7 Abdominal pain 3 (Sc) 0 KF848550
DSS36 F/5.9 Abdominal pain 3 (Sc) KF848551
DSS37 M/7.4 2 (Sc) 0 KF848552
DSS38 F/9.7 Abdominal pain, diarrhea, vomiting 1 (Sc) 0 KF848553
DSS39 F/9.8 Abdominal pain 3 KF848554
DSS40 F/9.9 Abdominal pain, diarrhea, vomiting 2 (Sc) KF848555
DSS41 F/9.7 Vomiting 3 (Sc) 0 KF848556
DSS42 F/10.2 Abdominal pain, diarrhea 1 (Sc) KF848557
DSS43 M/9.3 2 (Sc) KF848558
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Table 1 Clinical data and Blastocystis sp. STs among symptomatic and asymptomatic patients in Senegal (Continued)
DSS44 M/10 Abdominal pain 3 (Sc) KF848559
DSS45 F/8.9 Abdominal pain 3 (Sc) 0 to 14 KF848560-1
DSS46 F/10.2 Abdominal pain 3 KF848562
DSS47 F/10 3 (Sc) 0 KF848563
DSS48 M/9.8 3 (Sc) 0 KF848564
DSS49 F/10 2 (Sc) KF848565
DSS50 F/10.2 1 KF848566
DSS51 M/9.4 1 (Sc) KF848567
DSS52 M/9 Abdominal pain 1 (Sc) KF848568
DSS53 F/8.1 1 (Sc) KF848569
DSS54 M/8.5 Mixed 1 and 2 (Sc) 0 KF848570-1
DSS55 M/9.1 Abdominal pain 3 (Sc) KF848572
DSS56 F/8.6 1 (Sc) KF848573
DSS57 F/9.7 Abdominal pain 2 (Sc) KF848574
DSS58 M/9.3 Abdominal pain 2 (Sc) KF848575
DSS59 M/8.9 Abdominal pain 3 (Sc) KF848576
DSS60 F/8.8 3 (Sc) KF848577
DSS61 M/9.9 1 KF848578
DSS62 F/9.5 Abdominal pain 1 KF848579
DSS63 M/8.5 Abdominal pain 1 (Sc) KF848580
DSS64 M/6.2 Abdominal pain 3 (Sc) KF848581
DSS65 M/9.8 1 (Sc) KF848582
DSS66 F/9.9 Abdominal pain 2 (Sc) KF848583
DSS67 F/6.1 Abdominal pain Mixed 1 and 4 (Sc) 0 KF848584-5
DSS68 F/6.1 1 (Sc) 0 KF848586
DSS69 F/6.8 1 KF848587
DSS70 F/7.8 Abdominal pain 3 (Sc) KF848588
DSS71 F/6.7 Abdominal pain 3 KF848589
DSS72 M/6 Abdominal pain, vomiting 3 (Sc) KF848590
DSS73 F/7 Abdominal pain 3 (Sc) 0 KF848591
DSS74 M/8.5 3 KF848592
DSS75 M/5.9 Abdominal pain 3 KF848593
DSS76 M/8.1 Abdominal pain 1 KF848594
DSS77 M/6.6 Abdominal pain 3 (Sc) 2 to 12 KF848595-7
DSS78 M/6.9 Abdominal pain 2 KF848598
DSS79 M/8.4 3 (Sc) 0 to 11 KF848599-600
DSS80 M/6.1 3 KF848601
DSS81 F/5.9 Abdominal pain Mixed 2 and 3 (Sc) 0 KF848602-3
DSS82 F/9.8 Abdominal pain 3 (Sc) 0 KF848604
DSS83 M/6.4 1 KF848605
DSS84 F/9.2 2 (Sc) KF848606
DSS85 F/6.8 Abdominal pain, vomiting 3 (P) 3 to 5 KF848607-9
DSS86 F/6.6 Abdominal pain Mixed 1, 2 and 3 (P) KF848610-2
DSS87 M/9.9 Abdominal pain 3 (P) 0 KF848613
DSS88 M/9.5 1 (P) 0 to 1 KF848614-5
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In almost all molecular epidemiological studies con-
ducted to date, only one nucleic acid-based diagnostics
methodology was used to identify and subtype Blastocys-
tis sp. isolates in stool samples. Briefly, PCR screening of
fecal samples can be achieved using ST-specific sequence-
tagged-site (STS) primers or genus-specific primers with
subsequent sequencing for ST identification. Several re-
gions in the SSU rDNA gene have been proposed by dif-
ferent authors for sequencing [24] but the “barcode”
region designed by Scicluna et al. [40] has been extensively
used as in the present study. Advantages and limitations
of these two PCR approaches were recently largely dis-
cussed [24,42] and a comparative study using both tech-
niques recommended barcoding as the relevant method
for Blastocystis sp. diagnosis and subtyping [43]. However,
as confirmed from our data, direct sequencing of non-
qPCR products may be unsuccessful in the case of mixed
infections with more than one Blastocystis sp. ST in the
same sample. Therefore subtyping of isolates in mixed in-
fections requires cloning of the non-qPCR product and se-
quencing of several clones as previously suggested [44]. In
addition, about 24% of the samples have not been diag-
nosed as positive for Blastocystis sp. by non-qPCR
methods in our study. Hence, at this stage of our screen-
ing, the prevalence of the parasite was 76%, which greatly
underestimated its true prevalence as determined in a sec-
ond step by qPCR (100%). Consequently, our study con-
firmed the impact of detection methods to ascertain the
actual prevalence of Blastocystis sp. in human populations
and the interest and higher sensitivity of qPCR assays in
comparison to non-qPCR methods for epidemiological
surveys.
Although the prevalence of Blastocystis sp. never
reached 100% in any cohort studied so far, it was de-
scribed as very high in some developing countries spe-
cially, in children. By using non-molecular standard
methods, the prevalence of the parasite already exceeded
40% in communities in Venezuela [45], Peru [46],
Colombia [7], and in school children or orphanage in
Indonesia [6], Thailand [47], and Lebanon (El Safadi
unpubl.). Moreover, the prevalence of Blastocystis sp.
was around 60% in immigrants in the city of Naples
(southern Italy) who came for a large majority from
northern and western African countries [48]. In Libya,
the prevalence of the parasite has been previously re-
ported close to 30% [49]. In Senegal, although the preva-
lence of Blastocystis sp. had never been determined
before, intestinal parasites (protozoa and helminths) rep-
resent for a long time a major public health problem. In-
deed, the global prevalence of intestinal parasites in
children ranged from 32% to 84% depending on the
study areas [50-53]. Such impact of intestinal parasites
previously reported in the Senegalese population is
clearly in accordance with the pattern found for Blasto-
cystis sp. in the current study.
Distribution of Blastocystis sp. STs in the Senegalese
population and comparison with other African countries
In all the children, the expected SSU rDNA domains tar-
geted by non-qPCR and qPCR methods were amplified
and successfully sequenced. Each of the new SSU rDNA
gene sequences obtained in this study showed very high
similarity (98% to 100%) to homologous sequences of
the other Blastocystis sp. isolates reported so far. The
comparison with representative sequences of all known
Blastocystis sp. STs allowed the direct subtyping of the
new isolates (Table 1). As stated above, for 32 of the 93
samples, cloning of the non-qPCR product was neces-
sary for subtyping and 3 positive clones were arbitrarily
selected and sequenced. For 14 of these 32 samples, the
three sequenced clones were identical (Table 1). For 10
other samples presenting infection by a single ST, clones
showed 1 to 14 nucleotide differences between them. As
previously suggested [40,41], these nucleotide differences
may reflect either coinfection with two isolates of the
same ST or sequence variations between SSU rDNA
gene copies within the same isolate [23]. Interestingly,
the higher number of nucleotide difference between the
clones (11 to 14) was observed in children infected by
ST3. Recently, by analyzing and comparing respectively
SSU rDNA sequences or data from multilocus sequence
typing, Meloni et al. [44] and Stensvold et al. [54] re-
vealed substantial intra-ST diversity in ST3 and more
limited intra-ST2 and intra-ST4 variations. In either
Table 1 Clinical data and Blastocystis sp. STs among symptomatic and asymptomatic patients in Senegal (Continued)
DSS89 F/9.1 Diarrhea 3 (P) 0 KF848616
DSS90 F/9.5 3 (P) 0 to 1 KF848617-8
DSS91 F/9.4 1 (P) 0 to 3 KF848619-20
DSS92 F/6.1 Abdominal pain, diarrhea 3 (P) 0 to 3 KF848621-2
DSS93 M/6 3 (P) 0 to 1 KF848623-4
aAccording to the standard terminology including 17 STs [2]; (Sc) and (P): non qPCRs using the primer pair described by Scicluna et al. [40] and Poirier et al. [20],
respectively.
bDetermined in the common region of clones belonging to the same ST and sequenced for each sample.
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case, we have considered in the following analysis of our
data that two different clones of the same ST identified
in the same patient derived from the same isolate of
Blastocystis sp. For the last 8 samples, mixed infections
with two (6 samples) or three STs (2 samples) were iden-
tified (Table 2). The majority of the subtyped samples in-
cluded in the present study (85/93) represented single
infections. With the addition of 8 mixed infections con-
sisting of two or three different isolates, we analyzed a
total of 103 isolates. As summarized in Table 3, ST3 was
the most common Blastocystis sp. ST in our Senegalese
population (49.5%) followed by ST1 (28.2%), ST2 (20.4%)
and ST4 (1.9%). The distribution of STs was almost similar
between the three villages with a majority of infections at-
tributable to ST3. The only significant difference was that
ST1 followed at position 2 in Niandiane and Agniam
Towguel and at position 3 in Fanaye Diery.
The distribution of Blastocystis sp. STs in Senegal is
quite similar to that observed in a majority of countries
all over the world with a predominance of ST3 followed
by ST1 then ST2 or ST4 [5]. If we focused on the studies
previously conducted in Africa, the only available reports
concerned the ST distribution in Egypt [21,37,38], Libya,
Nigeria, Liberia [2], and Tanzania [39], the latter survey
only including 6 isolates (Figure 1). Globally, ST1, ST2,
and ST3 represent around 82% of all 369 African isolates
subtyped so far including those of the present study.
ST3 is highly prevalent in African countries with an
average of 46% of the 369 isolates. Consequently, be-
cause ST3 is rarely found in animals, a large-scale
human-to-human transmission might likely explain the
predominance of this ST in African countries as also in
the rest of the world. Three studies conducted in differ-
ent cities in Egypt and that in Liberia have identified
ST3 as the predominant ST, as was true for our study
population. However ST1 was detected with the highest
frequency in Libya and Nigeria, and ST2 in Tanzania.
Since ST1 and ST2 are frequently found in various ani-
mal groups including livestock [2,4,55], it can be hypoth-
esized that a not yet evaluated proportion of human
infections by both STs are of zoonotic origin. Interest-
ingly ST4 was not detected in the studies reported in
Egypt, Libya and Tanzania and its prevalence is quite
low in Senegal (1.9%). Although ST4 was relatively
frequent in Liberia (12%) and Nigeria (14%), these data
confirmed that ST4 is much less frequently detected or
absent in Africa while it is commonly found in Europe
[5,34]. However, the reasons for the heterogeneous geo-
graphical distribution of ST4 remain unknown and its
reservoir hosts have to be clarified. Additional STs in-
cluding ST6 and ST7 were commonly found only in two
studies carried out in Egypt [21,38]. Indeed, these STs
were not detected in Senegal, Liberia, Nigeria, and
Tanzania as in a third survey in Egypt [37] and only one
isolate belonging to ST7 was identified in Libya. Both
STs are usually hosted by birds (avian STs) [56] and
rarely found in mammals. This was confirmed in the
present study. Given their apparent host specificity, it is
highly likely that human infections by avian STs are of
zoonotic origin.
The prevalence of mixed ST infections was 8.6% (8/93
samples) in our Senegalese cohort. This percentage is
probably underestimated but roughly similar to that cal-
culated (6%) by taking into account subtyped isolates
from all epidemiological studies published to date (191
of 3171 samples) and listed by Alfellani et al. [5]. Mixed
ST infections were found in all three villages of our
study but with different proportions. In Agniam Towguel,
only one mixed infection by 3 STs was found (ST1/ST2/
ST3) (5.9%) while 4 mixed infections by 2 or 3 STs
(10.5%) (ST2/ST3, ST3/ST4 and ST1/ST2/ST3) were re-
corded in Fanaye Diery. Regarding Niandane, 3 mixed in-
fections by 2 STs (7.9%) were identified (ST1/ST2, ST1/
ST4, and ST2/ST3) (Table 2). Mixed infections mostly
corresponded to ST1, ST2, and ST3 isolates and were
more likely to occur considering the high prevalence of
each of these STs in our cohort. Curiously, the only two
ST4 isolates of our study were identified in the context of
mixed infections and not as part of single infections.
Distribution of Blastocystis sp. STs in symptomatic and
asymptomatic groups
According to recent epidemiological reports, links be-
tween ST and pathogenicity are still matter of debate
[8,29,33-36,41]. To highlight a possible relationship be-
tween ST and major intestinal symptoms associated with
Blastocystis sp. infection (diarrhea, vomiting, and abdom-
inal pain), the ST distribution was evaluated in our cohort
Table 2 Single and mixed ST infections with Blastocystis sp. identified in the Senegalese cohort
Villages Blastocystis sp. STs Total no.
ST1 ST2 ST3 ST1/ST2 ST1/ST4 ST2/ST3 ST3/ST4 ST1/ST2/ST3
Agniam Towguel 5 2 9 0 0 0 0 1 17
Niandane 13 5 17 1 1 1 0 0 38
Fanaye Diery 7 8 19 0 0 2 1 1 38
Total no. 25 15 45 1 1 3 1 2 93
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of 93 symptomatic or asymptomatic children. Interest-
ingly, the majority of children infected by Blastocystis sp.
(54/93 or 58%) presented various gastrointestinal disor-
ders as previously observed in a pediatric unit in Turkey
[57]. In the following analysis, symptomatic (6) and
asymptomatic (2) children presenting mixed infections by
two or three STs were removed. Thereby the remaining
48 isolates from symptomatic children and 37 isolates
from asymptomatic children were considered (Table 4).
The most dominant ST in both groups was ST3, and 63%
of the ST3 isolates were found in symptomatic individuals.
Predominance or high prevalence of ST3 in symptomatic
groups of patients was also shown for instance in France
[41], Australia [8], Turkey [57,58], and Iran [35]. Regard-
ing ST1 and ST2 isolates, both STs were detected with
equal frequency in the symptomatic and asymptomatic
groups of our cohort (Chi square test, p = 0.845). How-
ever, ST1 was over-represented in groups of symptomatic
individuals in previous epidemiological studies in China
[59], Turkey [60], Iran [35], Egypt [21], and Lebanon [36].
Moreover, ST1 was the most prevalent ST in some co-
horts presenting with IBS [38,61] and was shown to be
pathogenic in rat models of blastocystosis [21]. In con-
trast, ST2 was not usually overrepresented in groups of
symptomatic patients from different countries and
Dogruman-Al et al. [57] suggested that ST2 was a non-
pathogenic ST. However, in our study, the proportion of
ST2 isolates in symptomatic patients was far from negli-
gible. Moreover, all ST2 isolates identified in French and
Figure 1 Distribution of Blastocystis sp. STs across African countries. In the case of Senegal, distribution of STs in mixed infections indicated
by an asterisk in the histogram was detailed.
Table 3 Blastocystis sp. ST distribution among Senegalese
villages
Villages Blastocystis sp. STs (%) Total no.
ST1 ST2 ST3 ST4
Agniam Towguel 6 3 10 0 19
Niandane 15 7 18 1 41
Fanaye Diery 8 11 23 1 43
Total no. (%) 29 (28.1) 21 (20.3) 51(49.5) 2 (1.9) 103
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Australian sampling were from symptomatic individuals
[8,41]. To complete our observations, it can also be under-
lined that the only two ST4 isolates found in our study
were associated with symptoms but in the context of
mixed ST infections (associated to ST1 or ST3). There-
fore, the pathogenic potential of ST4 could not be
assessed from our epidemiological data. However, a high
prevalence of ST4 was recently found in Danish patients
presenting with acute diarrhea [33] and Spanish symp-
tomatic individuals [62]. Globally, no association between
ST and symptom status was statistically significant from
our present data.
Potential risk factors for transmission of Blastocystis sp.
within the Senegalese cohort
The fecal-oral route is the main mode of transmission of
Blastocystis sp. like the other common gastrointestinal
parasites [1]. To reach a prevalence of 100% as in the
present study, it is reasonable to argue that infection of
Senegalese children by the parasite occurred through
multiple transmission sources. Although we did not had
the opportunity to collect and analyze environmental
(mainly water samples) and animal samples, it appears
clear that individuals living in small communities in a
rural area with modest socio-economic status (average
income of 0.5 $ per person per day in these Senegalese
villages), poor hygiene sanitation, close contact with
domestic animals and livestock, and water supply dir-
ectly from well and river as in our study greatly increase
their risks of infection by Blastocystis sp. Indeed, recent
studies have revealed a human-to-human transmission
coupled with a high prevalence of the parasite in a close
community of girls in Thailand [13] as well as in a rural
village in Nepal [14] whose description and environment
(animals reared in or next to villager dwellings and rivers
as water sources of the community) are quite similar to
those of Senegalese villages. In this context, zoonotic
transmission of Blastocystis sp. would be another signifi-
cant source of infection due to the wide range of animals
potentially infected with the parasite and in close con-
tact with humans [2,4,55,56]. However the impact of
this mode of transmission through contact with contam-
inated animal fecal materials coupled with poor hand
hygiene of villagers remains difficult to quantify there-
fore that it involves STs frequently found in humans
(ST1 to ST4) as in the present study. Finally, there is a
concern that water should be a main source of infection
by Blastocystis sp. although large-scale waterborne out-
breaks involving the parasite have not yet been docu-
mented. Ability of Blastocystis sp. cysts, the only
transmissible stage of this parasite to survive for long
periods of time in the environment together with their
low size [1,15] represent some factors that favor water-
borne transmission of the parasite. In 2006, Blastocystis
sp. has also been added by the World Health Organi-
zation to the list of waterborne parasites [63]. Blastocys-
tis sp. was previously reported in drinking water, rivers,
tanks, and sewage samples [11,12,14,15,64]. Interestingly,
in these latter studies, the same STs were identified in
both the water samples and the stools of consumers pro-
viding evidence for water transmission. In the Senegalese
villages of the present study, river and wells represent
the main water sources for drinking and cooking pur-
poses as well as for bathing of the population. Conse-
quently, water sources of this community potentially
contaminated with human and animal feces, may largely
facilitate transmission of Blastocystis sp. and should be
considered as serious potential threats to consumers.
Further, the analysis of fecal samples from animals
living in or near the Senegalese villages and of water
samples would help to confirm their epidemiological
importance as sources of infection and contamination
for inhabitants.
Conclusions
To our knowledge, this is the first investigation of preva-
lence and ST distribution of Blastocystis sp. in Senegal
that, moreover, greatly expands the few data available on
molecular epidemiology of this parasite in Africa. In this
country, the prevalence of Blastocystis sp. in a cohort of
children living in a rural area reached a peak of 100%
never achieved before. Such high prevalence may reflect
different exposure of individuals to animal (zoonosis)
and environmental (waterborne) sources of infection to-
gether with large-scale human-to-human transmission.
This study also raises questions about the real pathogen-
icity of Blastocystis sp. since more than half of children
infected by this parasite presented various gastrointes-
tinal symptoms and highlights the socioeconomic impact
of blastocystosis in developing countries with low envir-
onmental conditions and quality of life. Finally, this epi-
demiological survey provides necessary information to
public health authorities for urgently setting prevention
(water quality assessments and primary education of
dwellers regarding the modes of transmission) and con-
trol programs that should help to reduce the burden of
Blastocystis sp.
Table 4 Distribution of Blastocystis sp. STs among
symptomatic and asymptomatic children groups
Group Blastocystis sp. STs (%) Total no.
ST1 ST2 ST3 Mixed
infections
Symptomatic 13 (24) 7 (13) 28 (52) 6 (11) 54
Asymptomatic 12 (31) 8 (20) 17 (44) 2 (5) 39
Total no (%) 25 (27) 15 (16) 45 (48) 8 (9) 93
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